Pictilisib (GDC-0941)

Catalog No.S1065 Synonyms: RG7321

Molecular Weight(MW): 513.64

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Cited by 294 Publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Eur J Pharmacol, 2020, 873:172981

PubMed: 32014486 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )
Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )
Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )
Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )
Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )
Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016, 15(12):2692-704

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )
Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )

Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )
PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )
Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )
Harvard University, 2014,

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )
Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )
Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	M4nqVmtqdmG\|ZTDBd5NigQ>?		MmHDNUBp	NHPFeVhFVVOR	M4PBemlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyZHXseIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDjc4V5eHKnc4PpcocheDh3YXzwbIEhf2m2aDDJR\|UxKG:oIECuNFA{KM7:TR?=	NWPIfphjOTh5NUS2OVQ>
Sf9	M3\hXmtqdmG\|ZTDBd5NigQ>?		NHv1SVIyKGh?	NVjPflQ2TE2VTx?=	M1TvTWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYnX0ZUBJOTB2Nz3SJI12fGGwdDDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGOxZYjwdoV{e2mwZzDwPFVidHCqYTD3bZRpKEmFNUCgc4YhOC5yMEOg{txO	MnzFNVg4PTR4NUS=
Sf9	MYjLbY5ie2ViQYPzZZk>		NWPme3M1OSCq	MoTySG1UVw>?	MYjJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGgSVU1PS2NIH31eIFvfCCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJINw\XiycnXzd4lv\yCyOEXhcJBp[SC5aYToJGlEPTBib3[gNE4xODNizszN	M3ziN\|E5PzV2NkW0
Sf9	MYPLbY5ie2ViQYPzZZk>		M1fq[VEhcA>?	NXP1W3J{TE2VTx?=	MXjJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMEOzJO69VQ>?	MlPXNVg4PTR4NUS=
Sf9	NWPuTWo3U2mwYYPlJGF{e2G7		MYSxJIg>	NH3jeGdFVVOR	NWfpUIFvUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDhcJBp[SCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJINw\XiycnXzd4lv\yCyOEXhcJBp[Q>?	NYruTGx6OTh5NUS2OVQ>
MDA-MB-361	M2fNXmZ2dmO2aX;uJGF{e2G7		MnXqNkBp	MYTEUXNQ	NUn6NWs2UW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNSGEuVUJvM{[xJINmdGy\|IIfpeIghWEmNM1PBJGU2PDVvSzDteZRifGmxbjD3bZRpKEmFNUCgc4YhOC5yMkig{txO	MX:xPFc2PDZ3NB?=
PC3	MVTGeY5kfGmxbjDBd5NigQ>?		M1HHUFIhcA>?	MVfEUXNQ	NHG5V21KdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDQR\|Mh[2WubIOge4l1cCCLQ{WwJI9nKDBwMEO3JO69VQ>?	MUKxPFc2PDZ3NB?=
U87MG	MVjGeY5kfGmxbjDBd5NigQ>?		NXLsW2V2OiCq	NFf6UYtFVVOR	NF7GWHpKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wOFYh\|ryP	M4TidlE5PzV2NkW0
MDA-MB-361	M1X4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXm5OkBp	NV:xNGtUTE2VTx?=	NUHEdm9XSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvM{[xJINmdGy\|IIfpeIghWEmNM1PBJGU2PDVvSzDteZRifGmxbjD3bZRpKEmFNUCgc4YhOC55MjFOwG0>	MYSxPFc2PDZ3NB?=
A2780	M2n1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3\Velk3KGh?	MkTNSG1UVw>?	NXLRTJg1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIGDJT\|NESSCjbnSgVHRGViCvdYTheIlwdiC5aYToJGlEPTBib3[gNE4yPCEQvF2=	MX:xPFc2PDZ3NB?=
PC3	M364V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYHWNIlRQTZiaB?=	MnXLSG1UVw>?	M3j4SmlEPTB;MD6yPEDPxE1?	NYLrUY5kOTh5NUS2OVQ>
U87MG	NIPacZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVG5OkBp	NU[zc2pmTE2VTx?=	NW\6bFhOUUN3ME2wMlk2KM7:TR?=	MY[xPFc2PDZ3NB?=
Sf9	MmPyT4lv[XOnIFHzd4F6		MYmzNEBucW5?	NVLseXBwTE2VTx?=	MlvKTY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHHtc5VvfCCxZjDBWHAh[2:wc4Xt[YQhf2m2aDDJR\|UxKG:oIECuNFQzKM7:TR?=	MnnLNlI2PDh\|NEK=
RAW 264.7	MnT6T4lv[XOnIFHzd4F6		NWTzSXk2QTBibXnu	M4\jc2ROW09?	NFO5NpJKdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vnZY1u[SCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjJ7ODFOwG0>	MmHaNlI2PDh\|NEK=
Sf9	NHX5cINMcW6jc3WgRZN{[Xl?		MV:xJIg>		M2HOd2lvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2tj\XSjIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVRkmgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODF5IN88US=>	MXGyN\|U1ODZ2NR?=
Sf9	M2nkZmtqdmG\|ZTDBd5NigQ>?		MXqxJIg>		Mnn5TY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4RmdHSjIHX4dJJme3OnZB?=	MUeyN\|U1ODZ2NR?=
Sf9	MoLaT4lv[XOnIFHzd4F6		MkHUNUBp		MUnJcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPL[4FudWFiZYjwdoV{e2Wm	M1\2[lI{PTRyNkS1
Sf9	M4H3T2tqdmG\|ZTDBd5NigQ>?		NWnlZ\|hmOSCq		MoDwTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4FteGijIHX4dJJme3OnZB?=	NYnySXpnOjN3NEC2OFU>
SKOV3	MVzLbY5ie2ViQYPzZZk>	NFy1dXkyKM7:TR?=	NELWcpcyKGh?	NHSzUG5FVVOR	NEHCVXhKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:w	NWi1XYVIOjN\|NkCzOFg>
MCF7	NGjVNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHlNUDPxE1?	NUDNVpZsQTZiaB?=	M3rhW2ROW09?	NEjnOVdIUTVyPUCuNFcxOiEQvF2=	NX;V[np5OjN\|NkCzOFg>
SKOV3	M2DpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7aUIkyKM7:TR?=	M1fEXlk3KGh?	MnvOSG1UVw>?	MoizS2k2OD1yLkG0O\|Yh\|ryP	M2\PWVI{OzZyM{S4
PC3	NV7iPJUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUjFRmRHPzJiaB?=	M3L3bWROW09?	M3i3S2lEPTB;MD6yPEDPxE1?	NHf6VmwzOTl6MUexOC=>
MCF7.1	NX3nfFBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXH0[2FRPzJiaB?=	MXTEUXNQ	M2DtfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{4yKGOnbHzzJIV5eHKnc4PpcochUEWUMjDn[Y5mKHerdHigTWM2OCCxZjCwMlI5KM7:TR?=	NF3McpEzOTl6MUexOC=>
MCF7-neo/Her2	M{TOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3S3cFczKGh?	MnTESG1UVw>?	NF\1S5NKSzVyPUCuNlkh\|ryP	NFPRZnMzOzZ4MkmwNy=>
MCF7-neo/Her2	NVniSINUU2mwYYPlJGF{e2G7				M1LjPWlvcGmkaYTpc44hd2ZiUFmzT4FteGijIHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:wIHH0JHM1PzNid3n0bEBKSzVyIH;mJFAvODB5IN88US=>	M3SzOVI{PjZ{OUCz
PC3	NXHLU41IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NES1ZZQ4OiCq	MoiySG1UVw>?	NHfBdGNGSzVyPUCuN\|Qh\|ryP	M4C4XVIyQTh3NkO5
MCF7.1	M2rVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2XJWlczKGh?	NX3pPGNjTE2VTx?=	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO\|aX7nJHBKO0ujbIDoZUBufXSjboSge4l1cCCHQ{WwJI9nKDBwM{mg{txO	M1L3[\|IyQTh3NkO5
PC3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M13wVVczKGh?	NFPIWINFVVOR	M{LBZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHTl[olkcWWwdDDpckBRXEWQIIfpeIghUUN3MDDv[kAxNjN7IN88US=>	NEfKPYkzODB3ME[2PS=>
MCF7.1	NEjYTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2nrUFczKGh?	M1PBRWROW09?	Mn65RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BRUTONYXzwbIEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkO0JO69VQ>?	M4TrfFIxODVyNk[5
MCF7.1	NYH2OXF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVK3NkBp		MoPaSWM2OD1yLkeyJO69VQ>?	NVzsZW1uOjB\|NE[2OVY>
NCI-H1975	MnW0R5l1d3SxeHnjJGF{e2G7		NFfpdYo4OiCq		MVrJR\|UxRTBwMkeg{txO	MofxNlMxPTl3NEW=
H460	M{PHPGN6fG:2b4jpZ{BCe3OjeR?=		M{ja[lczKGh?		NHnUSmxKSzVyPUCuPFch\|ryP	NXTyblQ3OjNyNUm1OFU>
HT-29	NIXGfmFEgXSxdH;4bYMhSXO\|YYm=		NFzRTWg4OiCq		NVzRXXhIUUN3ME2wMlY3KM7:TR?=	NFLKUVIzOzB3OUW0OS=>
HepG2	MljnR5l1d3SxeHnjJGF{e2G7		M{C3OVczKGh?		M{\1UmlEPTB;MTFOwG0>	MWiyN\|A2QTV2NR?=
SGC7901	MXPDfZRwfG:6aXOgRZN{[Xl?		MYO3NkBp		NG[4UHpKSzVyPUGuPEDPxE1?	MVqyN\|A2QTV2NR?=
NCI-H226	MmXSR5l1d3SxeHnjJGF{e2G7		NXXyfol[PzJiaB?=		M2D3UGlEPTB;Mj65JO69VQ>?	NE\HbIQzOzB3OUW0OS=>
A549	MVPDfZRwfG:6aXOgRZN{[Xl?		NIHkUXU4OiCq		M2WwUWlEPTB;Nj65JO69VQ>?	NUfUcIZbOjNyNUm1OFU>
U87MG	NYrDbJU4S3m2b4TvfIlkKEG\|c3H5		NWDWVnRGPzJiaB?=		NVu2fld3UUN3ME23Mlc4KM7:TR?=	NHfQbYczOzB3OUW0OS=>
HBC4	NIfQbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHsc4dIUTVyPT22MlA{KE1?	M4HnblIzOzN4MkS2
BSY1	NID4bnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnGclRXdG:pR1m1NF0uPi57MDDN	NHL2NmIzOjN\|NkK0Oi=>
HBC5	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfyeWltd2eJSUWwQU03NjZyIF2=	M{C5dFIzOzN4MkS2
MCF7	M{DKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3L3d4xw\0eLNUC9MVcvOzNiTR?=	M1PndlIzOzN4MkS2
MDA-MB-231	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nOfYxw\0eLNUC9MVUvPDZiTR?=	MX:yNlM{PjJ2Nh?=
U251	NIHlUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrMcI9oT0l3ME2tOU42OCCP	M1exNFIzOzN4MkS2
SF268	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\BcI9oT0l3ME2tOU4{QSCP	MnjtNlI{OzZ{NE[=
SF295	NF\4bINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHHNYVRdG:pR1m1NF0uPi5\|NzDN	MnzMNlI{OzZ{NE[=
SF539	M{jX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\sc4dIUTVyPT22MlUxKE1?	M{jRdVIzOzN4MkS2
SNB75	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml31cI9oT0l3ME2tO{4yOCCP	M1H4N\|IzOzN4MkS2
SNB78	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnOycI9oT0l3ME2tOk42OiCP	MWOyNlM{PjJ2Nh?=
HCC2998	NFHvO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHsc4dIUTVyPT22MlI6KE1?	M1Hje\|IzOzN4MkS2
KM12	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX[zU\|JbdG:pR1m1NF0uPS55NjDN	NYrZTm9NOjJ\|M{[yOFY>
HT-29	M4fFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;sc4dIUTVyPT22MlMxKE1?	MYOyNlM{PjJ2Nh?=
HCT15	NIrTUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEGyWYhtd2eJSUWwQU03NjF{IF2=	NGixWYQzOjN\|NkK0Oi=>
HCT116	NYjRUFc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHIcm5ndG:pR1m1NF0uPS56NzDN	Mnu0NlI{OzZ{NE[=
NCI-H23	MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFmydYVtd2eJSUWwQU02Njd\|IF2=	MmLDNlI{OzZ{NE[=
NCI-H226	NWnq[lJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;sc4dIUTVyPT22MlIyKE1?	NH\xSIMzOjN\|NkK0Oi=>
NCI-H522	NWXNU4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTsc4dIUTVyPT22MlU5KE1?	MXyyNlM{PjJ2Nh?=
NCI-H483	NE\UVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXRcI9oT0l3ME2tOk42PiCP	NYrYcohTOjJ\|M{[yOFY>
A549	M3zveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MomycI9oT0l3ME2tOk4yPSCP	NUHofXN3OjJ\|M{[yOFY>
DMS273	MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DKS4xw\0eLNUC9MVYvPDNiTR?=	MWKyNlM{PjJ2Nh?=
DMS114	NID5cZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPacI9oT0l3ME2tOU46OiCP	MmfiNlI{OzZ{NE[=
LOXIMVI	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3y0ZYxw\0eLNUC9MVYvOjliTR?=	NYDmVYFROjJ\|M{[yOFY>
OVCAR3	M1nSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jMfYxw\0eLNUC9MVYvPzFiTR?=	NGr2O\|IzOjN\|NkK0Oi=>
OVCAR4	NEXobHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4izfoxw\0eLNUC9MVUvPzZiTR?=	MYiyNlM{PjJ2Nh?=
OVCAR5	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnL5cI9oT0l3ME2tOk4zPiCP	MkDGNlI{OzZ{NE[=
OVCAR8	NUHONJA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnsc4dIUTVyPT21Mlc{KE1?	NGLGUXkzOjN\|NkK0Oi=>
SKOV3	NFu0blRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\sc4dIUTVyPT22MlUzKE1?	MWeyNlM{PjJ2Nh?=
RXF631L	MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\obYsxdG:pR1m1NF0uPi56ODDN	NUTNe4I2OjJ\|M{[yOFY>
ACHN	M1LaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjpS\|dtd2eJSUWwQU03NjB5IF2=	MX:yNlM{PjJ2Nh?=
St-4	NFXtW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUT3fYdPdG:pR1m1NF0uPS53NjDN	NF:5cZgzOjN\|NkK0Oi=>
MKN1	NW\ZXIl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlz4cI9oT0l3ME2tO{4xQCCP	MYmyNlM{PjJ2Nh?=
MKN7	M3P3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jqOIxw\0eLNUC9MVYvPTBiTR?=	NGS1TYYzOjN\|NkK0Oi=>
MKN28	NEHEbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGL3WWJtd2eJSUWwQU02NjV{IF2=	NGL5PZEzOjN\|NkK0Oi=>
MKN45	NYH3W5VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfLW2Jtd2eJSUWwQU03NjV3IF2=	MkXINlI{OzZ{NE[=
MKN74	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHftNnhtd2eJSUWwQU03NjB{IF2=	MVOyNlM{PjJ2Nh?=
DU145	MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4q4UYxw\0eLNUC9MVUvQDViTR?=	NH3hU44zOjN\|NkK0Oi=>
PC3	NXjCR5B3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nXTYxw\0eLNUC9MVYvPjZiTR?=	Mln6NlI{OzZ{NE[=
ES5	M2TGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLMNmtlUUN3ME21NE4zOSCwTR?=	M{fHWXNCVkeHUh?=
HH	NVHWTpAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXK0WZJvUUN3ME2xNVEvODhibl2=	M2H3UHNCVkeHUh?=
MHH-PREB-1	NXHPRm1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDUTWM2OD1zMUSuN{BvVQ>?	NXXkXWZZW0GQR1XS
NCI-H1770	NIG2TmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTF{Mz64OkBvVQ>?	NXe4SWJ4W0GQR1XS
HuO9	NEfaUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrsdIl[UUN3ME2yNFYvODJibl2=	NWPQbopbW0GQR1XS
HAL-01	Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIj3[mVKSzVyPUKwOk44OyCwTR?=	Ml\1V2FPT0WU
NOS-1	NYCxbYp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37EcmlEPTB;MkGxMlgzKG6P	NGHBVopUSU6JRWK=
HGC-27	NHHY[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1KwfmlEPTB;MkGyMlU4KG6P	NGfUeGpUSU6JRWK=
NB69	MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfwTWM2OD1{NEWuNlchdk1?	NGHEZXhUSU6JRWK=
RS4-11	M1;4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnP1TWM2OD1{NkGuO\|Yhdk1?	M1;xXXNCVkeHUh?=
DOK	M3TiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIizUFJKSzVyPUOwNU44KG6P	NILVXZZUSU6JRWK=
LB2241-RCC	MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlftTWM2OD1\|MEOuPFQhdk1?	NEnTbVBUSU6JRWK=
NCI-H1623	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrCbJl[UUN3ME2zNFQvODhibl2=	NH;INFVUSU6JRWK=
YH-13	NFjvNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWf0RoxFUUN3ME2zNFQvOzJibl2=	M13YSHNCVkeHUh?=
BPH-1	Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1e4emlEPTB;M{G0JI5O	MWHTRW5ITVJ?
AN3-CA	MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTN2MD6zO{BvVQ>?	NITKeYRUSU6JRWK=
ES7	NF:2NnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnmdolKSzVyPUO0NU46QSCwTR?=	MXXTRW5ITVJ?
MDA-MB-175-VII	NXvRWnMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\XVWh4UUN3ME2zOVIvQTJibl2=	M{O4bXNCVkeHUh?=
GAMG	M4LFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2OwVmlEPTB;M{ewMlg2KG6P	MULTRW5ITVJ?
CHL-1	NUDYe3BST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\q[lVKSzVyPUO3PE43PSCwTR?=	MXXTRW5ITVJ?
NB7	M{L3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7DXWZIUUN3ME2zPFkvQDNibl2=	NXLBSWZ4W0GQR1XS
MFE-280	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjBXGNKSzVyPUSxPE4zKG6P	M1P2UnNCVkeHUh?=
HL-60	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH6zUHJKSzVyPUSyOU44PSCwTR?=	MVnTRW5ITVJ?
GCIY	NVv5eHdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTR\|Mz64JI5O	M{OzcnNCVkeHUh?=
MDA-MB-361	MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTSTWM2OD12M{muNVMhdk1?	MYfTRW5ITVJ?
LXF-289	MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlv6TWM2OD12NEiuNlchdk1?	M1LxPHNCVkeHUh?=
NBsusSR	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLMRW9OUUN3ME20PFgvQDVibl2=	NUPaNmpzW0GQR1XS
KU-19-19	M3W0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDQOWFpUUN3ME21NVYvODdibl2=	MV;TRW5ITVJ?
A204	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37yR2lEPTB;NUKyMlM{KG6P	MY\TRW5ITVJ?
LB1047-RCC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTV{Mj65N{BvVQ>?	MVHTRW5ITVJ?
COLO-684	MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHxTWM2OD13MkOuNVEhdk1?	MX\TRW5ITVJ?
PA-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjwTWM2OD13M{KuOFEhdk1?	Mne4V2FPT0WU
MG-63	MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVr5WYZRUUN3ME21OFEvOTFibl2=	Mli0V2FPT0WU
BHT-101	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTV2ND65OEBvVQ>?	M3;UNHNCVkeHUh?=
NKM-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PVWGlEPTB;NUmzMlA6KG6P	NV7EVmpIW0GQR1XS
T47D	NHfYXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTV7Nz61OkBvVQ>?	NX\PSYRpW0GQR1XS
MOLT-4	NIHzR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTZ{Mz62NkBvVQ>?	MkXFV2FPT0WU
IGROV-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXUTWF[UUN3ME22N\|QvOzFibl2=	MlqyV2FPT0WU
ES4	M2nrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTFWHJ6UUN3ME22N\|kvPTRibl2=	MXrTRW5ITVJ?
HuO-3N1	NWTKZYptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTLTWM2OD14NEKuN\|ghdk1?	NGPIbHNUSU6JRWK=
NEC8	NUKyeWxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\ZfGlEPTB;NkWzMlU4KG6P	NF3mRndUSU6JRWK=
HO-1-N-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmr5TWM2OD14NUmuNVchdk1?	NEDEPGtUSU6JRWK=
EPCL-272H	NXXqSIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXewT2pLUUN3ME22PFcvOjFibl2=	M{PHV3NCVkeHUh?=
D-263MG	M132fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofPTWM2OD15MUiuNUBvVQ>?	NGrn[opUSU6JRWK=
MV-4-11	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTd{ND6zNUBvVQ>?	MmrpV2FPT0WU
SK-NEP-1	NXHQW3c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTd{NT65OEBvVQ>?	NGS0[4lUSU6JRWK=
SW872	NYf4NlVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnX[XlKSzVyPUeyO{45QSCwTR?=	MYXTRW5ITVJ?
P30-OHK	NH60d41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTd\|MD63NUBvVQ>?	NVLkbmRqW0GQR1XS
OMC-1	NVzXRYlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDJTWM2OD15NUGuNFkhdk1?	M3H5R3NCVkeHUh?=
LoVo	M3TTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;iNpNKSzVyPUe3O{46KG6P	MUjTRW5ITVJ?
LNCaP-Clone-FGC	M4jjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnrXZVKSzVyPUe5Ok4{PCCwTR?=	MmXKV2FPT0WU
L-363	M4PRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;hdXpKSzVyPUe5PE41OiCwTR?=	MnLJV2FPT0WU
ES8	MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHnPI9HUUN3ME24NVAvPTJibl2=	NXL4RYtyW0GQR1XS
697	NWXvUFlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVm0fIhFUUN3ME24N\|EvPTVibl2=	M1r4OnNCVkeHUh?=
HSC-3	M4nPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXVe2JKSzVyPUizPU42PCCwTR?=	NFzJcmxUSU6JRWK=
H4	MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXLdpNKSzVyPUi1NE45PSCwTR?=	M{L4NHNCVkeHUh?=
QIMR-WIL	M{nY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPEbJA4UUN3ME24OlUvOiCwTR?=	M4XCOXNCVkeHUh?=
OAW-42	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fNSmlEPTB;OEeyMlE6KG6P	MYrTRW5ITVJ?
MCF7	NWC3elNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrDW4NKSzVyPUi5PE42QSCwTR?=	NVnpOG5OW0GQR1XS
SCC-25	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DYVmlEPTB;OUG0MlE6KG6P	M1ewbnNCVkeHUh?=
NCI-H1563	MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvyZ5lWUUN3ME25NVUvQTlibl2=	MorQV2FPT0WU
OVCAR-5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLEUnlKSzVyPUm0NE4yPyCwTR?=	NYW5dpNxW0GQR1XS
HDLM-2	Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4r6UmlEPTB;OUS5MlIhdk1?	M{nPVnNCVkeHUh?=
NB5	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvPeVZKSzVyPUm1Ok43KG6P	NH\0fZlUSU6JRWK=
NCI-H292	NF;5bY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPKcpRtUUN3ME25O\|QvOzJibl2=	M1LBUXNCVkeHUh?=
A101D	M2W3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF[4XFRKSzVyPUm5NE4yQSCwTR?=	NEPGOnlUSU6JRWK=
NCI-H1648	M3nQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zQUmlEPTB;OUm4MlUyKG6P	M1\ZSnNCVkeHUh?=
EKVX	NWLk[oxIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXwOJZKSzVyPUGuNFEzQSEQvF2=	NHLxcmNUSU6JRWK=
SW1710	NWe5UJBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPYbFduUUN3ME2xMlA1OjN\|IN88US=>	NE\2V4lUSU6JRWK=
WM-115	M13XOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HZUmlEPTB;MT6wOlY2PiEQvF2=	MmPBV2FPT0WU
CAL-54	MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTFwMEewPFEh\|ryP	MV7TRW5ITVJ?
TGBC24TKB	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkm3TWM2OD1zLkC4NFQ2KM7:TR?=	MnXkV2FPT0WU
NCI-H520	MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkm4TWM2OD1zLkC4PVY4KM7:TR?=	Mn6yV2FPT0WU
D-423MG	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVza[4hSUUN3ME2xMlA6QTZ{IN88US=>	NELjPHhUSU6JRWK=
BFTC-905	NGD5boxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTFwMUO0OFkh\|ryP	NYPWRlZQW0GQR1XS
HT	NUnKdI9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTITWM2OD1zLkGzOFc5KM7:TR?=	NEDuOXVUSU6JRWK=
CTB-1	NYSzbIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\hTWM2OD1zLkG0Nlk{KM7:TR?=	NXfkdWZjW0GQR1XS
Hs-578-T	MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrqTWM2OD1zLkG5OVY2KM7:TR?=	M4Kzb3NCVkeHUh?=
HuH-7	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPqeIxSUUN3ME2xMlIxQTR7IN88US=>	MWDTRW5ITVJ?
LB996-RCC	NH\zW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjoTWM2OD1zLkKyNVc4KM7:TR?=	NWrCN\|YzW0GQR1XS
KYSE-270	M{K0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfyTWM2OD1zLkK5O\|M1KM7:TR?=	M3z1PHNCVkeHUh?=
A4-Fuk	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTFwMkm5PVMh\|ryP	NVX4R4p1W0GQR1XS
A498	NEP3R4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfHSYlKSzVyPUGuN\|A1PzRizszN	NInBVm5USU6JRWK=
SK-MEL-1	NVr5ZopET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;kTWlEPTB;MT6zNFY4QSEQvF2=	M3\BR3NCVkeHUh?=
AU565	NUjMXldIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFwM{G4OlMh\|ryP	NUW4RlRGW0GQR1XS
Saos-2	NXrUbYlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTFwM{OyNFUh\|ryP	NUfUU2pjW0GQR1XS
A549	NX\LbJZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfFV5hCUUN3ME2xMlM6QTdizszN	NF7YXVlUSU6JRWK=
BFTC-909	MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLncVNxUUN3ME2xMlQ{OzB3IN88US=>	NUnoeYxFW0GQR1XS
MDA-MB-415	M1PUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nxPWlEPTB;MT60PFY6OiEQvF2=	M4fqcHNCVkeHUh?=
639-V	NEew[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPkXZBKSzVyPUGuOVAzPDVizszN	MWTTRW5ITVJ?
A704	NF\Ue\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn31TWM2OD1zLkWwO\|g2KM7:TR?=	NGHNS5hUSU6JRWK=
PANC-03-27	M{LRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnnO3hKSzVyPUGuOVE1ODhizszN	MXTTRW5ITVJ?
SK-MEL-28	NXvGeI11T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3ReIdEUUN3ME2xMlU3ODh3IN88US=>	MXPTRW5ITVJ?
Ramos-2G6-4C10	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPNXJFqUUN3ME2xMlYxPzR4IN88US=>	NHXNPFFUSU6JRWK=
HuP-T4	MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rkZmlEPTB;MT62NFc4QCEQvF2=	MWPTRW5ITVJ?
VA-ES-BJ	NY\iOYFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXzU\|NKSzVyPUGuOlEzPyEQvF2=	MXXTRW5ITVJ?
EFM-19	NGHMXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTFwNkG4NUDPxE1?	NUSyRWhUW0GQR1XS
G-401	M{K4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfu[JZ6UUN3ME2xMlYzOTZ2IN88US=>	MXrTRW5ITVJ?
D-566MG	M1exOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LkT2lEPTB;MT62NlU{KM7:TR?=	MUjTRW5ITVJ?
JVM-3	M3XMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTFwNkS4O\|Uh\|ryP	MlPvV2FPT0WU
TK10	M{XZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml32TWM2OD1zLk[3NFg{KM7:TR?=	NFXObZZUSU6JRWK=
BT-20	MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfTRpNKSzVyPUGuOlg6ODJizszN	NH;i[4tUSU6JRWK=
EGI-1	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\aW\|hKSzVyPUGuPFQ4ODFizszN	Ml\NV2FPT0WU
EW-16	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfNTWM2OD1zLki1NVgzKM7:TR?=	NWjheIs3W0GQR1XS
NCI-H2228	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2KzOmlEPTB;MT64OVIxOyEQvF2=	MWjTRW5ITVJ?
BB49-HNC	NVLWVoRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYX1VZpjUUN3ME2xMlg5Pjl{IN88US=>	NHPhPWlUSU6JRWK=
G-402	M{PSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLXOGZKSzVyPUGuPFk4QTdizszN	MkLqV2FPT0WU
NCI-H526	MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVOyXmRDUUN3ME2xMlkyOzlizszN	MUHTRW5ITVJ?
ME-180	NUDUeFU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\FTWM2OD1zLkmzOFc4KM7:TR?=	NILOPGtUSU6JRWK=
PFSK-1	NXfXUXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\EXWlEPTB;MT65OFQ2QCEQvF2=	M123dnNCVkeHUh?=
TYK-nu	NEK1eVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1n2TmlEPTB;MT65OVgzOyEQvF2=	NEXVfFVUSU6JRWK=
HOS	Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTFwOUe5OFgh\|ryP	NWPiNm0xW0GQR1XS
T98G	MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTjTWM2OD1zLkm5NFA3KM7:TR?=	M3LTVnNCVkeHUh?=
SK-MES-1	NF3PfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTOTWM2OD1{LkCxN\|MzKM7:TR?=	NEHlWWVUSU6JRWK=
SNB75	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlL5TWM2OD1{LkCxOVQyKM7:TR?=	NGi4NppUSU6JRWK=
LAMA-84	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2O2PGlEPTB;Mj6wNlY5QSEQvF2=	M2fLO3NCVkeHUh?=
CAL-39	NF\kcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfRTWM2OD1{LkCzNlgh\|ryP	MYjTRW5ITVJ?
LOXIMVI	M33zUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;iNWVKSzVyPUKuNFQxQDRizszN	NFvHTXlUSU6JRWK=
NH-12	MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTJwMEW0NlQh\|ryP	NWjYVZdSW0GQR1XS
NCI-H1048	M2mzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;5dVFoUUN3ME2yMlExPTJizszN	NIDqVWlUSU6JRWK=
KS-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPTSY9KSzVyPUKuNVExODFizszN	MUfTRW5ITVJ?
NCI-N87	NXznN2ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33FOmlEPTB;Mj6xN\|M5PCEQvF2=	NV;uNXdWW0GQR1XS
CHP-212	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHySGZjUUN3ME2yMlE5PDR{IN88US=>	NWrrS4dCW0GQR1XS
HCC1419	NFn3RVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHS5VGpKSzVyPUKuNlEyOTVizszN	NGiy[oxUSU6JRWK=
ES1	NVnidppOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfFPGRxUUN3ME2yMlIyOzJ4IN88US=>	MXvTRW5ITVJ?
NCI-H2030	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTJwMkSxNlMh\|ryP	MnjOV2FPT0WU
EW-22	Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoD3TWM2OD1{LkK1NFY4KM7:TR?=	NXnteG5[W0GQR1XS
A431	Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTJwMkezOVQh\|ryP	NHf5OG1USU6JRWK=
SF126	M1LzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTJwM{C2NlUh\|ryP	MULTRW5ITVJ?
SF295	NVzEdFFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nnVWlEPTB;Mj6zNVUzPCEQvF2=	MV3TRW5ITVJ?
D-502MG	NVXMSWxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTJwM{K0OlEh\|ryP	M{XlZnNCVkeHUh?=
HCC2157	NYfNeXFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGC2fJhKSzVyPUKuN\|I6OjdizszN	NHTmVYhUSU6JRWK=
D-283MED	NFrifo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLvTWM2OD1{LkO1PVI3KM7:TR?=	M2XHenNCVkeHUh?=
SNU-423	M2P3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTJwNECxO\|Eh\|ryP	M2LBVXNCVkeHUh?=
SK-LU-1	Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nLe2lEPTB;Mj60OFU5PiEQvF2=	MYXTRW5ITVJ?
22RV1	NF\hVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLWTXhCUUN3ME2yMlQ2PjF5IN88US=>	NWD4dZF[W0GQR1XS
SW1088	MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTJwNEmyNVMh\|ryP	NX;HT5lbW0GQR1XS
HT-3	NWSwTYs6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEL5O2ZKSzVyPUKuOFkzPTlizszN	MULTRW5ITVJ?
NCI-H1666	M3XaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTJwNUGxNFQh\|ryP	NIm1XWtUSU6JRWK=
EM-2	MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPzbY1KSzVyPUKuOVEyPjlizszN	M2fs[nNCVkeHUh?=
SNU-449	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DDRWlEPTB;Mj61O\|AyPCEQvF2=	Mk\mV2FPT0WU
786-0	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHQcoN2UUN3ME2yMlU6OjN6IN88US=>	NUHvZmdGW0GQR1XS
SKG-IIIa	NIC3NXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37UXmlEPTB;Mj62OVk{QSEQvF2=	NXzpXVB4W0GQR1XS
MEL-HO	NVLxbGt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTJwNke2N\|Qh\|ryP	MnPtV2FPT0WU
LCLC-97TM1	M4jz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3jTWM2OD1{Lk[5NlY4KM7:TR?=	NXvIRplHW0GQR1XS
MKN7	MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XkZmlEPTB;Mj63NFc2PCEQvF2=	MW\TRW5ITVJ?
5637	NVjGcFJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoO5TWM2OD1{LkexNFM2KM7:TR?=	NGj4TmJUSU6JRWK=
HOP-92	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJwN{S3NVch\|ryP	MULTRW5ITVJ?
MDA-MB-157	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLMZ4hKSzVyPUKuPFIxOjNizszN	MlzzV2FPT0WU
NB12	M3rOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTJwOES5NVQh\|ryP	NHfVW5RUSU6JRWK=
DMS-273	NW\sboE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7KfHlKSzVyPUKuPFY1PyEQvF2=	NV\5U5RnW0GQR1XS
HCC70	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH71eZVKSzVyPUKuPFY2QDlizszN	MoT2V2FPT0WU
YKG-1	Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTNwMEO3PFch\|ryP	MmTpV2FPT0WU
NCI-H28	NVy2NHR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjaTWM2OD1\|LkC1NlkyKM7:TR?=	M12zbnNCVkeHUh?=
HN	NYfiOJdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\1TWM2OD1\|LkC2OlM3KM7:TR?=	MYrTRW5ITVJ?
HT-1080	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHuTWM2OD1\|LkC4OlA3KM7:TR?=	Mn:2V2FPT0WU
HPAF-II	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XYWmlEPTB;Mz6xNFA3QCEQvF2=	M4LvSXNCVkeHUh?=
U-2-OS	M2nBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3y0dmlEPTB;Mz6xN\|c5OiEQvF2=	NIf1RpRUSU6JRWK=
SNU-387	M{jSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPlTWM2OD1\|LkG2N\|Y1KM7:TR?=	M2LKbXNCVkeHUh?=
Becker	NHL6TJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLzUZJKSzVyPUOuNVY5ODhizszN	M{XDeXNCVkeHUh?=
BHY	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPNTWM2OD1\|LkK1OVcyKM7:TR?=	NHfSTY1USU6JRWK=
HTC-C3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTNwMkmzOVIh\|ryP	NE[2UFFUSU6JRWK=
M14	MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTNwM{C2OlMh\|ryP	NFvUbJZUSU6JRWK=
COR-L23	M1jvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY[2XIFkUUN3ME2zMlM4Ojd7IN88US=>	M17RdnNCVkeHUh?=
C32	M2Xhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTNwNEG1NFgh\|ryP	MVfTRW5ITVJ?
Mewo	M4rXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17kNGlEPTB;Mz60NlE5OiEQvF2=	MnLGV2FPT0WU
TE-8	Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrPTWM2OD1\|LkS4NlU6KM7:TR?=	NWLNS2pKW0GQR1XS
RPMI-2650	M2PoUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE[2SHBKSzVyPUOuOlA3OzdizszN	NWj4UpY3W0GQR1XS
AGS	NXvkbJAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fES2lEPTB;Mz62NlQ3PCEQvF2=	NFXvb4tUSU6JRWK=
MZ2-MEL	NF;HblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTNwNk[xN\|gh\|ryP	NH;yU41USU6JRWK=
Calu-3	NWTLdG5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjw[41KSzVyPUOuO\|EzQDdizszN	MYXTRW5ITVJ?
SJSA-1	M{HiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fsc2lEPTB;Mz63NVMyPSEQvF2=	MXfTRW5ITVJ?
SW962	NVLwNmZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3GT3RCUUN3ME2zMlczPjN4IN88US=>	NYjKZ\|NyW0GQR1XS
PC-14	NEO2RVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PNRWlEPTB;Mz63N\|IzOiEQvF2=	MoiwV2FPT0WU
SW1573	NHrpT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTNwN{WzOFgh\|ryP	Mn3qV2FPT0WU
769-P	NVTmOWl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTNwOEK3OFMh\|ryP	M3i3bXNCVkeHUh?=
KNS-62	NXjLd5dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTNwOUKzN\|gh\|ryP	NXz3XmQ4W0GQR1XS
NCI-H747	NH3OdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjjT2lKSzVyPUSuNFU3OzhizszN	NYS5Z\|F5W0GQR1XS
LN-405	M3vmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\CcHlMUUN3ME20MlE2PzJ6IN88US=>	NUTCPG1bW0GQR1XS
OVCAR-8	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\STWM2OD12LkKyOVQ{KM7:TR?=	NVj1PWxnW0GQR1XS
DMS-114	Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\CfG1YUUN3ME20MlI{QDlzIN88US=>	NX7PO5R{W0GQR1XS
NCI-H2126	NWLZNW4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTRwMkS1OVgh\|ryP	MVvTRW5ITVJ?
TCCSUP	NVf6SZB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnLTWM2OD12LkK0O\|g5KM7:TR?=	NFvDUJhUSU6JRWK=
SK-N-FI	NW[4WlR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTRwMkWzN\|Ih\|ryP	NYrITYgyW0GQR1XS
HCE-4	NGjI[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHOTWM2OD12LkK3NVk4KM7:TR?=	NUPIXY1EW0GQR1XS
DK-MG	NFrjWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjjcXNKSzVyPUSuN\|A{QSEQvF2=	NGeyPHBUSU6JRWK=
RO82-W-1	M3ezUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XTRWlEPTB;ND6zNlU5PCEQvF2=	M{HPU3NCVkeHUh?=
A2780	M4r5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3JdoJKSzVyPUSuN\|Y3QDJizszN	NV;lWFBPW0GQR1XS
ETK-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3L2SmlEPTB;ND6zO\|A2OiEQvF2=	NVrwNpBbW0GQR1XS
FADU	NFzzWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnqTWM2OD12LkO3OFY4KM7:TR?=	Mlr0V2FPT0WU
CAL-12T	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTDTWM2OD12LkSxOFE{KM7:TR?=	NEGwenFUSU6JRWK=
647-V	NXfHSlVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TsOGlEPTB;ND60OFAzOiEQvF2=	NYmyVXVZW0GQR1XS
TGBC1TKB	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPXTWM2OD12LkS1NVE{KM7:TR?=	MmjjV2FPT0WU
LU-99A	NGHrW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rOeGlEPTB;ND60OlA3KM7:TR?=	NUL2eYl1W0GQR1XS
CAL-33	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TkOWlEPTB;ND61NlQ2PiEQvF2=	Mmi2V2FPT0WU
LU-134-A	NH7uO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnZdnpGUUN3ME20MlUzPzR3IN88US=>	MVXTRW5ITVJ?
NCI-H1355	M37EcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHiTWM2OD12LkW1NVQ3KM7:TR?=	M{nL[nNCVkeHUh?=
RPMI-7951	NYDMZnZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TCcWlEPTB;ND61O\|AxOiEQvF2=	NVfUcoRJW0GQR1XS
TE-1	M4fGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTRwNk[xOFMh\|ryP	MnXNV2FPT0WU
OE33	NGTnZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\FcpBKSzVyPUSuO\|A2OTFizszN	MVTTRW5ITVJ?
CAL-51	M3jNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTRwN{GwPFIh\|ryP	M{DNcnNCVkeHUh?=
SW1783	NFO4e\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmP5TWM2OD12Lke1N\|A5KM7:TR?=	MWDTRW5ITVJ?
BT-474	NUnmUHRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HBfmlEPTB;ND63OlM5PCEQvF2=	NYL1bHV1W0GQR1XS
KYSE-520	NGnHNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nxXmlEPTB;ND64O\|M6OiEQvF2=	MX\TRW5ITVJ?
8-MG-BA	M2XRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDYTWM2OD12Lki4OVU4KM7:TR?=	MYTTRW5ITVJ?
IA-LM	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHI[WNKSzVyPUSuPVk1OzVizszN	NEX1VIJUSU6JRWK=
SW954	M{P0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvBbGhnUUN3ME20Mlk6PDR\|IN88US=>	Mli3V2FPT0WU
RPMI-8226	MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPvRXFKSzVyPUWuNFU1PjFizszN	NEHh[oVUSU6JRWK=
MKN1	MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLpTWM2OD13LkC3PVI4KM7:TR?=	NEKyXW9USU6JRWK=
A375	MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVv5[4tGUUN3ME21MlA6OjV4IN88US=>	MYnTRW5ITVJ?
8305C	NYPwR3VjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{Pqc2lEPTB;NT6wPVg5PyEQvF2=	MkjEV2FPT0WU
CAL-62	NEO5PHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHG0OnVKSzVyPUWuNVgzPTlizszN	MWPTRW5ITVJ?
NB10	M1OzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnJTWM2OD13LkKyO\|Q1KM7:TR?=	MXvTRW5ITVJ?
OC-314	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorkTWM2OD13LkO3OFQ1KM7:TR?=	MXLTRW5ITVJ?
PSN1	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTVwM{iyPFYh\|ryP	M1jXXXNCVkeHUh?=
GR-ST	NYHNdoh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDpTWM2OD13LkO4N\|IzKM7:TR?=	M3i5bHNCVkeHUh?=
P12-ICHIKAWA	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;PTWM2OD13LkSwNUDPxE1?	NX72RYVzW0GQR1XS
NCI-H1092	M{n1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn60TWM2OD13LkSxNVQ5KM7:TR?=	NV[3[JBRW0GQR1XS
SCC-4	M{DxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1z5NmlEPTB;NT60NVM2PSEQvF2=	NGHSNVhUSU6JRWK=
TE-6	NYXPVXF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXhTWM2OD13LkSxPFE3KM7:TR?=	MVLTRW5ITVJ?
DOHH-2	Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTVwNEKyOFgh\|ryP	NVv0RlA1W0GQR1XS
SW684	NIrGZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{WwOGlEPTB;NT62OlM5PSEQvF2=	NH3zb2xUSU6JRWK=
CP50-MEL-B	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTVwNki2PFQh\|ryP	NUnPWpJGW0GQR1XS
UM-UC-3	NIrLbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfmRpVKSzVyPUWuO\|IzOzFizszN	M3fPZnNCVkeHUh?=
LC-2-ad	NVXsboZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLOeIlpUUN3ME21Mlc5OjVzIN88US=>	NFP5b5dUSU6JRWK=
PC-3	NVf3co51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTVwOUG2NVUh\|ryP	M{Prb3NCVkeHUh?=
CAN	M2HsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTyTWM2OD13LkmyPFIh\|ryP	M{HoVHNCVkeHUh?=
ESS-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PIfGlEPTB;NT65O\|g3QSEQvF2=	MXzTRW5ITVJ?
ATN-1	M{m0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXsTphKSzVyPU[uNFU2PjhizszN	M3nMR3NCVkeHUh?=
BxPC-3	M1HVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV75eWJJUUN3ME22MlA5OjF7IN88US=>	M2nEXnNCVkeHUh?=
KYSE-150	NWXXRohJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTrW4NUUUN3ME22MlEzPDd4IN88US=>	M3TiZ3NCVkeHUh?=
RPMI-8866	NEnab3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjBSWRKSzVyPU[uNVkyPjNizszN	NF25SXRUSU6JRWK=
SW780	NUHNbXVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3JTWM2OD14LkKwOFIh\|ryP	Mk\UV2FPT0WU
A388	MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrYWG9OUUN3ME22MlI{OTF3IN88US=>	NGi1T3JUSU6JRWK=
NCI-H1437	NY\MT4JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHmwTWRKSzVyPU[uNlQxPzNizszN	MVTTRW5ITVJ?
NCI-H1755	M165[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\0VGlEPTB;Nj6zOlYyOiEQvF2=	NX7YendFW0GQR1XS
LS-123	MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3LTWM2OD14LkSwOVIyKM7:TR?=	Mn31V2FPT0WU
CaR-1	MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTZwNE[zO\|Mh\|ryP	MoX2V2FPT0WU
RT-112	MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfkTWM2OD14Lk[wN\|M5KM7:TR?=	MnLzV2FPT0WU
CGT	M{XJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXKTWM2OD14LkezOlgyKM7:TR?=	M{fMS3NCVkeHUh?=
SW626	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfiZm57UUN3ME22Mlc{QTR4IN88US=>	M1LCPHNCVkeHUh?=
AsPC-1	NIOwWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLkTWM2OD14Lke0OVA4KM7:TR?=	MYDTRW5ITVJ?
SBC-5	MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LiT2lEPTB;Nj65O\|I6PyEQvF2=	NUjkXZdwW0GQR1XS
SF539	MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Pkb2lEPTB;Nj65PVM{OyEQvF2=	NU\STVVNW0GQR1XS
TI-73	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnoTWM2OD15LkC2Nlg2KM7:TR?=	MYHTRW5ITVJ?
MHH-ES-1	NXridJdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PE[GlEPTB;Nz6wO\|c3OiEQvF2=	M17rZXNCVkeHUh?=
KYSE-510	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfEVYZJUUN3ME23MlA5PDN{IN88US=>	NFTwN4FUSU6JRWK=
EW-1	NIXhOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWiwb5pXUUN3ME23MlM3QTl4IN88US=>	M3fqOXNCVkeHUh?=
SK-OV-3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;NSGlGUUN3ME23MlM6PDN{IN88US=>	NWD6TmpWW0GQR1XS
MC-IXC	NVTQUlNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2[1fmlEPTB;Nz60NVk4OiEQvF2=	M2jLR3NCVkeHUh?=
HSC-2	M3jYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGX6OYxKSzVyPUeuOFI4ODVizszN	NFzJPHlUSU6JRWK=
NCI-H2342	MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTdwNUG0PUDPxE1?	M4WwNHNCVkeHUh?=
NCI-H1792	NWfFZm5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWW0O\|NyUUN3ME23MlUyPzFzIN88US=>	MojNV2FPT0WU
HT-1376	Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3uW\|JKSzVyPUeuPFc4PzhizszN	MmLzV2FPT0WU
EW-13	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTdwOEm5O\|ch\|ryP	MmHlV2FPT0WU
no-11	NWHtb5lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDyWplKSzVyPUeuPVAyPzRizszN	M{DzeHNCVkeHUh?=
Daoy	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVKxTYJYUUN3ME23Mlk1OzJzIN88US=>	M1fTWXNCVkeHUh?=
COLO-800	M4DmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvpOYVKSzVyPUiuNFQyPjJizszN	M1LPUnNCVkeHUh?=
GB-1	NGrpSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRThwME[1OlUh\|ryP	NGX5S\|JUSU6JRWK=
SJRH30	NFe4U2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHWeIZwUUN3ME24MlE2QDd6IN88US=>	M2i1eXNCVkeHUh?=
NCI-H2291	NFm2Z5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjKTHVKSzVyPUiuNlkyQDdizszN	NIT6bXdUSU6JRWK=
J82	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRThwMkm0PVEh\|ryP	NF\2UZlUSU6JRWK=
NCI-H596	NIHTN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PNdmlEPTB;OD6zNVQ2OyEQvF2=	MUDTRW5ITVJ?
RERF-LC-MS	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHJTWM2OD16LkO0PFU3KM7:TR?=	MVvTRW5ITVJ?
RH-18	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjoNW5KSzVyPUiuN\|UxPDZizszN	M3XpNnNCVkeHUh?=
SW48	M1j1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRThwNUm0OVMh\|ryP	MWTTRW5ITVJ?
RD	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPBZZJKSzVyPUiuOVk{QTFizszN	NYToOVhjW0GQR1XS
MS-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRThwNkGzPFch\|ryP	M3;KRnNCVkeHUh?=
ES6	M2TERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjKO2NqUUN3ME24Mlc{OTF7IN88US=>	MojIV2FPT0WU
TE-12	M{fFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3Hic2lEPTB;OD63O\|UxPSEQvF2=	NV;JW4M4W0GQR1XS
DBTRG-05MG	NHz4R2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrqR3dKSzVyPUiuPVEzOTdizszN	MWDTRW5ITVJ?
KINGS-1	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vNT2lEPTB;OD65Nlk{QCEQvF2=	MnW4V2FPT0WU
HLE	M1PvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRThwOUO3PFUh\|ryP	NY\kOGtYW0GQR1XS
MHH-NB-11	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTlwMEG4N\|kh\|ryP	MXLTRW5ITVJ?
U-87-MG	M{Xjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDuXHdKSzVyPUmuNlQ{OjFizszN	NVvPbFh4W0GQR1XS
MN-60	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnHR2pKSzVyPUmuNlQ2PDJizszN	M3TJNXNCVkeHUh?=
SAS	NUfPOmxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTlwMkW1PFEh\|ryP	NH7icFlUSU6JRWK=
NCI-H446	M17Te2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\HfWlEPTB;OT6zOlEh\|ryP	NWridWhOW0GQR1XS
C-33-A	M4ruN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrtTmVvUUN3ME25MlQ{QTh6IN88US=>	NUK4U3JIW0GQR1XS
RXF393	M2LRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{W3dWlEPTB;OT60O\|AxOiEQvF2=	M1fEbHNCVkeHUh?=
CGTH-W-1	MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFSy[XVKSzVyPUmuOFk{QDRizszN	MYLTRW5ITVJ?
RCM-1	NEDheGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTlwNkO4NFEh\|ryP	MonBV2FPT0WU
SN12C	NW\jNmtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmD2TWM2OD17Lk[1N\|M5KM7:TR?=	NGTTZWhUSU6JRWK=
KLE	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTlwN{CwNFkh\|ryP	MUTTRW5ITVJ?
EFO-21	M1u4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInIO2ZKSzVyPUmuO\|c{QDJizszN	MV3TRW5ITVJ?
KYSE-70	MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTlwOEiwNVEh\|ryP	NG\CSFNUSU6JRWK=
D-247MG	NIPWV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M16yPGlEPTB;MUCuNFU3QCEQvF2=	NE\TeGlUSU6JRWK=
MPP-89	NH7GNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zyN2lEPTB;MUCuNFk1PiEQvF2=	MnvvV2FPT0WU
RVH-421	M1i0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTFyLkG1NFUh\|ryP	NYjHRWZlW0GQR1XS
NCI-H460	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTFyLkK4NFYh\|ryP	MXLTRW5ITVJ?
NOMO-1	MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkToTWM2OD1zMD6zOVMzKM7:TR?=	M3XVOnNCVkeHUh?=
DEL	M3zxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTFyLkO3PVQh\|ryP	M3K2XnNCVkeHUh?=
HT55	NVfpXHgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nZO2lEPTB;MUCuOlIxPSEQvF2=	MUHTRW5ITVJ?
MC116	M2THSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHzVmF7UUN3ME2xNE43PjV3IN88US=>	MoP5V2FPT0WU
BB30-HNC	NXLUS\|EyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvZRWYzUUN3ME2xNE43PjlizszN	NHy4bI9USU6JRWK=
DJM-1	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTFyLk[5OFkh\|ryP	M3\uZ3NCVkeHUh?=
ZR-75-30	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFj1e3ZKSzVyPUGwMlk1PDFizszN	NHPoeFhUSU6JRWK=
U-118-MG	NUPG[Ws1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXz5bXVvUUN3ME2xNE46QDl4IN88US=>	NH\aOGxUSU6JRWK=
MSTO-211H	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYS3W451UUN3ME2xNU4xPzF4IN88US=>	M1;wOHNCVkeHUh?=
SW837	NFTCW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PvXmlEPTB;MUGuNFk1QSEQvF2=	MWnTRW5ITVJ?
HuCCT1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PabGlEPTB;MUGuNVI5OSEQvF2=	Ml;PV2FPT0WU
RCC10RGB	M3\KTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHxTWM2OD1zMT6xN\|Uh\|ryP	NILxe5BUSU6JRWK=
NMC-G1	NFfCUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofiTWM2OD1zMT6xOFk{KM7:TR?=	M4XLZ3NCVkeHUh?=
NCI-H650	NFzHTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1i0PGlEPTB;MUGuN\|c6PCEQvF2=	MmPIV2FPT0WU
HEC-1	NGHadIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonBTWM2OD1zMT60N\|I5KM7:TR?=	NGO0U5JUSU6JRWK=
DU-4475	M1LGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYH5boNQUUN3ME2xNU44Ozl\|IN88US=>	NG\RXFZUSU6JRWK=
DSH1	MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37QOWlEPTB;MUGuO\|YxPiEQvF2=	NYD5Ulg3W0GQR1XS
HCC1569	NV7iN4FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIn3TVFKSzVyPUGxMlc3PzhizszN	NYWxeVNHW0GQR1XS
HCC1187	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHYTWM2OD1zMT64OVg5KM7:TR?=	MXfTRW5ITVJ?
EW-11	MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfOZ4YzUUN3ME2xNU46PDd2IN88US=>	NXzRWoZMW0GQR1XS
LB2518-MEL	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXKzeoRrUUN3ME2xNk4xPTlizszN	MY\TRW5ITVJ?
KALS-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nkZmlEPTB;MUKuPFU2OyEQvF2=	Ml3OV2FPT0WU
8505C	M1LRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3voSWlEPTB;MUKuPFg2KM7:TR?=	NH31NWZUSU6JRWK=
SK-N-DZ	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rLXWlEPTB;MUOuNFQ2OyEQvF2=	M{DW[HNCVkeHUh?=
CHP-134	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfhW2JRUUN3ME2xN{4yOTV6IN88US=>	NVqwfoxPW0GQR1XS
HCE-T	M2XybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M371cGlEPTB;MUOuNlM3PCEQvF2=	NF7lbG5USU6JRWK=
LB-831-BLC	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLlZZdWUUN3ME2xN{43OjR4IN88US=>	NHrKfoJUSU6JRWK=
OVCAR-4	NX30b5J2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTF\|Lk[1NlQh\|ryP	NVSxNodWW0GQR1XS
SW756	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jlSGlEPTB;MUOuO\|I1PiEQvF2=	MUXTRW5ITVJ?
OCUB-M	MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;VSnlKSzVyPUGzMlgyPTZizszN	MXTTRW5ITVJ?
SW982	NHnHcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jwUWlEPTB;MUOuPFI4PiEQvF2=	MWrTRW5ITVJ?
DB	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTkOGxSUUN3ME2xN{45Ozh2IN88US=>	MYDTRW5ITVJ?
H-EMC-SS	NXLUWI05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLFTWM2OD1zMz65NVM6KM7:TR?=	MXTTRW5ITVJ?
VMRC-RCZ	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHq3WY5KSzVyPUG0MlAxOTVizszN	M2TtUHNCVkeHUh?=
CAKI-1	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF73c4NKSzVyPUG0MlAyOzJizszN	MkDsV2FPT0WU
GI-1	M2DaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DJWWlEPTB;MUSuNFY2QCEQvF2=	NH7qc4RUSU6JRWK=
Ca9-22	M2WwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\KOIRrUUN3ME2xOE43ODV2IN88US=>	Mn;LV2FPT0WU
TE-5	M4G0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fXUWlEPTB;MUSuO\|IxQCEQvF2=	NEDlWGdUSU6JRWK=
EFO-27	M2LnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXGNoRKSzVyPUG0Mlc3OjJizszN	NWP2[XZCW0GQR1XS
CAL-72	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTF2Lke3PFMh\|ryP	M3S3NHNCVkeHUh?=
GP5d	M2P5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTF3LkC0O\|Qh\|ryP	Mk\0V2FPT0WU
CAS-1	NXH3W21QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jtfWlEPTB;MUWuNFY3KM7:TR?=	MUDTRW5ITVJ?
A2058	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mor2TWM2OD1zNT61OlM5KM7:TR?=	MkjTV2FPT0WU
PANC-08-13	M2nQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXETWM2OD1zNT62PFU6KM7:TR?=	M1OwcnNCVkeHUh?=
Detroit562	MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVL1VVQ5UUN3ME2xOU46OTN7IN88US=>	MkDBV2FPT0WU
PANC-10-05	NXTKRm9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnCTWM2OD1zNj6wPFIyKM7:TR?=	NEH5cpZUSU6JRWK=
KOSC-2	MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\tcWFuUUN3ME2xOk4yOTJ3IN88US=>	NXvCZYdvW0GQR1XS
GT3TKB	NXfPcIo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\TUlk{UUN3ME2xOk4yQThzIN88US=>	MX;TRW5ITVJ?
KM-H2	NEj3PXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTF4LkO2OFYh\|ryP	NU\3WVBpW0GQR1XS
LB771-HNC	M4\mNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTDTWM2OD1zNj60OFIzKM7:TR?=	MX;TRW5ITVJ?
SF268	Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TpW2lEPTB;MU[uOFUzKM7:TR?=	NYTPOVRrW0GQR1XS
OE19	NVP2cWx[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjWcGdxUUN3ME2xOk42OjRizszN	NIG3N5pUSU6JRWK=
MLMA	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\KdlFKSzVyPUG2MlU2PzFizszN	MWHTRW5ITVJ?
MDA-MB-231	NHqxWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTVcVhDUUN3ME2xOk44OTN4IN88US=>	NIDLb3BUSU6JRWK=
TGW	NED5eG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTF4LkixNFIh\|ryP	M{fic3NCVkeHUh?=
MDA-MB-453	M{S0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjyXoZWUUN3ME2xO{4xODB\|IN88US=>	MVXTRW5ITVJ?
SNU-C2B	NXHCUYVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTF5LkCyN\|ch\|ryP	Mlr5V2FPT0WU
A427	NFKwbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTF5LkKzN\|Qh\|ryP	MYPTRW5ITVJ?
SK-MEL-2	M1;yWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\CWmlEPTB;MUeuN\|IyOyEQvF2=	NXXUNGxYW0GQR1XS
KURAMOCHI	Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvoTWM2OD1zNz6zPFk4KM7:TR?=	NIfTPWVUSU6JRWK=
IST-MEL1	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXryOYc6UUN3ME2xO{46OTh{IN88US=>	M4DsW3NCVkeHUh?=
NCI-H1793	NWDWNVhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTUTWM2OD1zOD6xOVgyKM7:TR?=	MlXBV2FPT0WU
HCC1395	NW\M[YxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2i4T2lEPTB;MUiuOVYyOSEQvF2=	M4H4THNCVkeHUh?=
NUGC-3	NYHSeGFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnkcXVZUUN3ME2xPE43PTh2IN88US=>	NUXCcJJkW0GQR1XS
BB65-RCC	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjpV3BNUUN3ME2xPE43PjlizszN	NFLEeJpUSU6JRWK=
RMG-I	NW\zXnQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHraU4dKSzVyPUG4Mlc{QDJizszN	MWXTRW5ITVJ?
LS-513	NWraeI5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTkS4lKSzVyPUG4MlkzOjhizszN	M3jF[XNCVkeHUh?=
MFM-223	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTF7LkC3NVYh\|ryP	MYTTRW5ITVJ?
NCI-H727	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HScGlEPTB;MUmuN\|I6PSEQvF2=	NUPmO3E2W0GQR1XS
KP-4	MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXHTWM2OD1zOT64OVMyKM7:TR?=	NVfYNYYxW0GQR1XS
NB13	MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DDXWlEPTB;MUmuPFg{QSEQvF2=	M37tT3NCVkeHUh?=
UACC-893	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTF7Lkm3OVch\|ryP	Ml\CV2FPT0WU
HT-1197	NHfYO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HLVmlEPTB;MkCuNlk2QCEQvF2=	NFXI[oZUSU6JRWK=
NCI-H2029	NETB[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\LTWM2OD1{MD6zNlY3KM7:TR?=	M2fTOXNCVkeHUh?=
GI-ME-N	Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjR[\|hoUUN3ME2yNE4{Ozd\|IN88US=>	MUPTRW5ITVJ?
OVCAR-3	NFHt[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPINlQxUUN3ME2yNE42QDJ{IN88US=>	MX\TRW5ITVJ?
HD-MY-Z	NHvQWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVi0VJlnUUN3ME2yNU4{Pjl4IN88US=>	Ml\qV2FPT0WU
NTERA-S-cl-D1	NHrOTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M370VmlEPTB;MkGuOlczOiEQvF2=	NX;zXWVtW0GQR1XS
SCH	NXzHSnB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTJ{LkS5OkDPxE1?	NVXnWYRIW0GQR1XS
KARPAS-299	NGHIT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTJ\|LkO4PFch\|ryP	Mo\FV2FPT0WU
NCI-H1650	NGTk[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LXW2lEPTB;MkOuPVI1OSEQvF2=	NIHVb5pUSU6JRWK=
ACHN	NVH0b2luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTJ2LkS2OVYh\|ryP	MoW4V2FPT0WU
M059J	M3nOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zGWGlEPTB;MkSuOVY{PCEQvF2=	NGWxXndUSU6JRWK=
AM-38	M{\kZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTJ3LkS4NUDPxE1?	MVPTRW5ITVJ?
KG-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3faRWlEPTB;MkWuOVQ6PCEQvF2=	MWnTRW5ITVJ?
COLO-824	NFzTWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLwTWM2OD1{NT61OVk6KM7:TR?=	NYTWRW9oW0GQR1XS
NCI-H1155	NYTyOIY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzLW5BQUUN3ME2yOU42QDR5IN88US=>	M{LtcHNCVkeHUh?=
NCI-H441	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PzZWlEPTB;MkWuO\|Q3PSEQvF2=	MVXTRW5ITVJ?
J-RT3-T3-5	MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\T[mlEPTB;Mk[uN\|AzPyEQvF2=	Moj0V2FPT0WU
JEG-3	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nsO2lEPTB;Mk[uOlgxPSEQvF2=	NWPi[IozW0GQR1XS
RKO	NYfNeJZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlW3TWM2OD1{Nj63OlMzKM7:TR?=	Mm\2V2FPT0WU
CAL-85-1	NV;INGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3JTG97UUN3ME2yO{4zOTF6IN88US=>	Ml7rV2FPT0WU
CAL-120	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHtTWM2OD1{Nz62PVE1KM7:TR?=	MVvTRW5ITVJ?
NCI-H2452	MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTJ5Lke3NVYh\|ryP	M4HmUnNCVkeHUh?=
NCI-H1395	MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DhfWlEPTB;MkeuO\|g{OyEQvF2=	MnzlV2FPT0WU
KYSE-450	NEHHe2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTWTWM2OD1{Nz65PFYzKM7:TR?=	M1HMfXNCVkeHUh?=
S-117	M2nyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2O5b2lEPTB;MkmuN\|g2PyEQvF2=	NIG0S\|lUSU6JRWK=
SW13	M3PrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHwSXZbUUN3ME2yPU45PTF7IN88US=>	NULjN5ptW0GQR1XS
ES3	NEjDNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nqXWlEPTB;M{CuN\|c{OyEQvF2=	NWLwO45FW0GQR1XS
HCT-116	NVnHWZJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTaTWM2OD1\|MD61OVU1KM7:TR?=	M{m1THNCVkeHUh?=
NCI-H1693	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{X6PGlEPTB;M{CuOVk1OiEQvF2=	NGnYPWZUSU6JRWK=
VM-CUB-1	M{\T[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDONIY2UUN3ME2zNE43PDF\|IN88US=>	NXzrelV2W0GQR1XS
NCI-H2170	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTyUG1KSzVyPUOxMlU4QDRizszN	NYqwUmhSW0GQR1XS
ALL-PO	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmL1TWM2OD1\|MT64OFI5KM7:TR?=	Ml\CV2FPT0WU
NCI-H661	MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLZdoZpUUN3ME2zNk4xPjJ\|IN88US=>	Ml3iV2FPT0WU
NCI-H2347	M1K2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fvRWlEPTB;M{KuOFg{PyEQvF2=	NIDVbZpUSU6JRWK=
FTC-133	NYi4eldLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7iVGpOUUN3ME2zNk44ODZizszN	NELIbppUSU6JRWK=
COLO-829	NEXKdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTN\|LkO0Olch\|ryP	NHi3fHRUSU6JRWK=
GOTO	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmn0TWM2OD1\|Mz61NlU5KM7:TR?=	M1\QdXNCVkeHUh?=
YAPC	MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nIRWlEPTB;M{OuPFE2QSEQvF2=	NHfrUVJUSU6JRWK=
LCLC-103H	M4eyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;V[oVKSzVyPUO0MlE3OjRizszN	M4ewT3NCVkeHUh?=
SiHa	M17hXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nFd2lEPTB;M{SuN\|gyPyEQvF2=	NUToWWJ2W0GQR1XS
LK-2	MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTN2LkW3NFgh\|ryP	MXrTRW5ITVJ?
KP-N-YS	NH3tWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTN2LkeyNFIh\|ryP	NEXxWnVUSU6JRWK=
NCI-SNU-1	M4fPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTN3LkG3PUDPxE1?	NGK3Wo9USU6JRWK=
KNS-81-FD	M{nmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTN3Lk[2N{DPxE1?	M2K4SXNCVkeHUh?=
SCC-9	M3HPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTN4LkexOFYh\|ryP	NWnIUpM4W0GQR1XS
SH-4	NF2yemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHNNnBmUUN3ME2zOk44OyEQvF2=	NWnhZ3k2W0GQR1XS
HCC-1954	Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDtPJBKSzVyPUO3MlI4OjlizszN	NEnsW3dUSU6JRWK=
BALL-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTEPHhkUUN3ME2zO{42OzF4IN88US=>	MWnTRW5ITVJ?
BE-13	NGj5XpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TBR2lEPTB;M{euO\|AyQCEQvF2=	NXX3bFdtW0GQR1XS
COLO-678	NGLKN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTN5Lkm0N\|ch\|ryP	NGrjfoFUSU6JRWK=
SK-MEL-3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfjTWM2OD1\|OD6yN\|k4KM7:TR?=	NETSS2xUSU6JRWK=
OAW-28	MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTN6Lk[zPUDPxE1?	NGH3S2NUSU6JRWK=
CAMA-1	NYG5PGpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmH5TWM2OD1\|OD65OlkyKM7:TR?=	NGC2[npUSU6JRWK=
C2BBe1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULTSoUxUUN3ME2zPU45OThizszN	MlLhV2FPT0WU
A3-KAW	M1KxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjDcGFKSzVyPUSwMlM3PjFizszN	MX3TRW5ITVJ?
SK-MEL-24	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml63TWM2OD12MD61PVMyKM7:TR?=	NY[xXG5ZW0GQR1XS
KYSE-140	M4Pse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zXbmlEPTB;NECuO\|E3PSEQvF2=	NVf3Z5BEW0GQR1XS
MOLT-16	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPte3BKSzVyPUSxMlE2OzZizszN	NYHEXo5oW0GQR1XS
CFPAC-1	NH7RNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWSxcIxEUUN3ME20Nk42OjFzIN88US=>	MVnTRW5ITVJ?
NB14	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XteGlEPTB;NEKuO\|AzPyEQvF2=	M1m1e3NCVkeHUh?=
COLO-792	NXvaXVRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV20UWFqUUN3ME20Nk45QTZzIN88US=>	MmS4V2FPT0WU
RH-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTR\|LkS4N\|Yh\|ryP	NEK3fY1USU6JRWK=
NCI-H522	M161eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\qTWM2OD12ND6zOVY5KM7:TR?=	NHLw[JJUSU6JRWK=
Ca-Ski	NEOxO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTR2LkixNVQh\|ryP	M{\jXXNCVkeHUh?=
KGN	NHXSTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkD6TWM2OD12OD6zNFY{KM7:TR?=	M3\CSnNCVkeHUh?=
UACC-62	NVfRRppoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfNd5JKSzVyPUS4MlQxPzJizszN	M3vGNHNCVkeHUh?=
NCI-H358	NYPWOFVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInLTG1KSzVyPUS5MlMxOThizszN	NXLwZ5lSW0GQR1XS
LS-411N	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHHTWM2OD12OT6zNVE5KM7:TR?=	MoDlV2FPT0WU
IST-MES1	M{CwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\yPY46UUN3ME20PU42PjJ3IN88US=>	M{XoUXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	- Collapse Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Formulation: Dissolved in 10% DMSO, 5% Tween 20, 85% water Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	RG7321

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Dactolisib (BEZ235, NVP-BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)

Cited by 294 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Pictilisib (GDC-0941) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)

Cited by 294 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Pictilisib (GDC-0941) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)